A PHASE II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer (BTC): IMBRAVE151
IMbrave 151 (NCT04677504) is a randomized, double-blind, placebo-controlled Phase II trial of atezolizumab + bevacizumab in combination with chemotherapy as first-line treatment for patients with advanced biliary tract cancer. This oral presentation reports the safety and efficacy of atezolizumab + bevacizumab in combination with gemcitabine and cisplatin in the IMbrave151 study.